Huons decided to absorb its subsidiary Huons Lab. Merger ratio 1:0.4256943, issuing 3,825,373 new shares (24.20% dilution).
Merger purpose: strengthen new drug pipeline, build full biopharma value chain, and leap to global pharma/biotech. Short-term R&D costs expected to increase.
Huons Lab had negative equity of -1.8B KRW and net loss of 10.2B KRW as of end-2025. Merger aims to improve profitability through operational efficiency and synergies.
If stock appraisal rights exercised exceed 30B KRW (Huons) or 4B KRW (Huons Lab), the board may cancel the merger. Appraisal price set at 32,886 KRW.
Special committee of outside directors and external experts reviewed fairness and procedural propriety. Shareholder meeting scheduled for Aug 21, 2026 (postponed from Jul 16).
[AI Comprehensive Analysis]This merger involves significant 24.2% dilution and the target has weak financials, raising concerns about short-term shareholder value erosion. However, the long-term potential from R&D and production synergies suggests a neutral to mildly negative outlook.
KOSDAQ Filing Information
Filing: [Correction of Description] Report On Major Matters (Decision On Company Merger)